Sibeprenlimab, formerly known as VIS649, represents a novel monoclonal agent demonstrating considerable potential in the management of antibody-mediated diseases . This distinct approach blocks C5a, a https://blakeitxk716821.blog5.net/92073195/sibeprenlimab-a-deep-examination-into-vis649-s-capability